Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Sign up Log in

Evotec SE Investor Presentation 2011

Feb 10, 2011

151_ip_2011-02-10_3a89c621-43ab-44ff-a976-115ee8127720.pdf

Investor Presentation

Open in viewer

Opens in your device viewer

Building innovative drug discovery alliances

Best in Class Drug Discovery Evotec acquires Kinaxo o

Evotec AG Management, Munich / Hamburg, 10th February 2011

Forward-looking sstatements

Information set forth in this presen forward-looking statements, which invo risks anduncertainties ncertainties. S ch u forward forward-lo include, but are not limited to, statem expected 2010 financial results and fina 2011, our anticipated financing needs, our on our liquidity guidance, our belief that to sustainable profitability latest in 2012, and assumptions concerning regulato business strategies, the progress odevelopment programmes and ti commencement and results of our clinicacollaborations and management s' plans strategies. These statements are neith guarantees, but are subject to a vari euncertainties, many of which are beyond which could cause actual results to differthose contemplated in these forward forward-loo In particular, the risks and uncertaintie other things: risks that product candidat clinic or may not be successfully manufactured; the risk that we will anticipated benefits of our collaboratio and acquisitions in the timeframes expect relating to our ability to advance the product candidates currently in the pipe trials; our inability to further identify, dev ntation containsolve a number ofooking statements ments about ourancial growth in r ability to deliver we are on courseour expectations ory, clinical and of our clinical iming of the al trials, strategic s objectives and er promises nor ety of risks and d our control, and r materially from oking statements statements.s include, among tes may fail in the y marketed or not achieve theons, partnerships ted, or at all; risks e development of eline or in clinicalvelop and achieve

commercial success for new products and technologies; the risk that competing products may be more successful; our inabilit to interest potential partners in o r technologies inability ourand products; our inability to achieve commercial success for our products and technologies; our inability to protect our intellectual property and the cost of enforcing or defending our intellectual property rights; our failure to , comply with regulations relating to our products and product candidates, including FDA requirements; the risk that the FDA may interpret the results of our studies differently than we have; the risk that clinical trials may not result in marketable products; the risk that we may be s, unable to successfully secure regulatory approval of and market our drug candidates; and risks of new, changing and competitive technologies and regulations in the U.S. and internationally.

The list of risks above is not exhaustive. Our most recent Annual Report on Form 20-F filed with the Securities and 20F, Exchange Commission, and other documents filed with, or furnished to the Securities and Exchange Commission, contain additional factors that could impact our businesses and financial performance. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based.

Expanding leaders ship in drug discovery

Acquisition rational

  • • Prop y gy p p rietary technology platform and cap drug efficacy and safety (discerning com y abilities for early and best decisions in mpound from target related effects)
  • • Key gy g p technology for strategic expansion o alliance business (in preclinical but also of oncology g y focused drug discovery clinical settings)
  • • Innovative platform and capabilities for t discovery (response prediction) translational medicine approach to drug
  • • Expected Kinaxo revenues in 2011 ca. € more than 30% yoy expected 2.5m; strong revenue growth rate of
  • • Approx. € 12m initial purchase price and Financed with € 3m initial cash consider out in cashd € 4m potential performance payment. ration, 2.6m shares 1), up to € 4m earn-

Agenda

•Strategic Background

  • • Integration in Evotec's D Drug Discovery alliance business
  • • Financial implications & & Outlook

Based on technoloogy from Max-Planck

History of Kinaxo

  • F d d i 2005 b• Founded in by Prof. Axel Ullrich, Henrik Daub, Andreas Jenne, and investors
  • • Based in Martinsried, Munich, Germany
  • • Based on worldwide, exclusive technology gylicenses from the Max-Planck Institute
  • Pi t Fi t Private company, significant VC capital and public support raised

•

  • • Chemical Proteomics and Phosphoproteomics, offered as services and used inhouse for biomarker development Phos Prof
  • • Firstwith l t i ll b ti long term service collaborations T d 25 big pharma
  • • Cont infradiag tract research to expand company astructure in personalized cancer nostics
  • • Thremultclinicee developed technologies, with tiple applications in early discovery, cal support and repositioning: pp p g technology within sphoScout®; Cellular Target iling® and KinAffinity®
  • •Today approx. scientists
  • • Acquisition and Integration into Evotec AG
  • • Strategy to leverage Kinaxo's world class gy Evotec's portfolio of drug discovery alliances

High quality leade r in external innovation

General industry trends w where Kinaxo supports Evotec´s mission

"External innovation" of fully integrated drug discovery projects 2

Discovery gy y g in oncology as key growth mar rket

R di ti k d i i Response prediction as a key decision parameter 4

Kinaxo strengthens Evotec's response Evotecto current challenges in drug discovery market

3

Agenda

  • •Strategic Backgound
  • • Integration in Evotec's s Drug Discovery Alliance Business
  • • Financial implications & & Outlook

Kinaxo s' technoloin all disease areaogies applicable s with focus on oncology

Integration rational

Today's platforms s

Overview of Evotec technoology platforms

H
T
S		 f
S
f
P
i
i
h
l
H
T
h
i
h
l
b
l
d
N
M
R
i
t
t
t
t,
r
o
p
r
e
a
r
s
c
r
e
e
n
n
g
e
c
n
o
o
g
o
o
r
g
c
o
n
e
n
a
e
r
e
e
a
n
s
c
r
e
e
n
n
g
y
y
•
,
f
B
i
l
i
l
i
t
t
t-
t
e
s
n
c
a
s
s
s
s
e
e
u
u
p
p
o
r
v
r
u
a
s
c
r
e
e
n
n
g
•
E
V
O
l
i
™
f
l
f
b
d
d
d
i
l
f
t
t-
t
u
o
n
p
o
w
e
r
u
r
a
g
m
e
n
a
a
s
e
r
u
g
s
c
o
v
e
r
y
p
a
o
r
m
:
•
C
i
i
d
l
d
h
i
h
h
h
i
t
t
t
t
o
r
e
e
x
p
e
r
s
e
n
a
s
s
a
y
e
v
e
o
p
m
e
e
n
a
n
g
r
o
u
g
p
u
s
c
r
e
e
n
n
g
•
U
i
d
l
l
i
d
i
f
f
i
d
h
h
l
i
l
d
d
i
i
t
t
t
t
t
t
t
n
q
u
e
c
o
m
p
o
u
n
c
o
e
c
o
n
e
r
e
e
n
a
e
r
o
u
g
q
u
a
y,
n
o
v
e
y
a
n
v
e
r
s
y
•
M
d
i
i
l
h
i
t
e
c
n
a
c
e
m
s
r
y		 E
i
d
k
d
f
i
l
l
j
h
i
d
l
t
t
t
t
t
t
x
p
e
r
s
e
a
n
a
r
a
c
r
e
c
o
r
o
s
u
c
c
c
e
s
s
n
a
m
a
o
r
e
r
a
p
e
u
c
a
r
e
a
s
a
n
a
r
g
e
c
a
s
s
e
s
•
S
b
d,
i
l
d
i
i
l
i
d-
b
d
d
i
t
t
t
t
r
u
c
u
r
e-
a
s
e
r
a
o
n
a
e
s
g
n
e
x
x
p
e
r
s
e
o
r
g
a
n
a
s
e
e
s
g
n
•
F
l
l
i
d
b
i
l
f
i
i
d
i
i
t
t
t
t
n
e
g
r
a
e
o
o
g
o
r
n
r
o
a
n
n
o
s
p
p
o
r
u
y
y
v
v
v
u
•
C
i
l
t
t
o
m
p
a
o
n
a
u
i
h
&
t
c
e
m
s
r
y
l
b
i
l
t
t
s
r
u
c
u
r
a
o
o
g
y		 I
d
i
l
h
i
d
l
b
i
l
b
i
l
i
i
t
t
t
t
t
t
t
t
n
e
g
r
a
e
c
o
m
p
u
a
o
n
a
c
e
m
s
r
y
y
a
n
s
r
u
c
u
r
a
o
o
g
y
c
a
p
a
e
s
•
S
d
l
i
d-
b
d
d
i
h
l
i
h
l
d
l
i
f
f
l
d
h
i
h
h
t
t
t
r
u
c
u
r
e
a
n
g
a
n
a
s
e
e
s
g
n
e
c
n
o
o
g
e
s
o
m
o
o
g
y
m
o
e
n
g,
s
c
a
o
o
p
p
n
g,
p
a
r
m
a
c
o
p
o
r
e
:
•
d
i
i
i
i
i
l
i
h
i
(
Q
S
A
R
)
t
t
t
t
t
t
t
t
t
s
u
e
s,
q
u
a
n
a
v
e
s
r
u
c
u
r
e
a
c
v
v
y
r
e
a
o
n
s
p
P
h
l
&
a
r
m
a
c
o
o
g
y
i
l
t
o
x
c
o
o
g
y		 L
d
i
f
l
i
f
i
i
A
D
M
E
T
T
t
t
e
a
n
g
p
o
r
o
o
o
n
v
r
o
a
s
s
a
y
s
•
L
L
d
d
i
i
b
b
f
f
i
i
h
h
i
i
l
l
f
f
f
f
i
i
d
d
d
d
f
f
f
f
i
i
i
i
i
i
i
i
i
i
f
f
h
h
l
l
d
d
t
t
t
t
t
t
t
t
t
t
t
t
e
a
n
g
z
e
r
a
s
s
c
r
e
e
n
n
g
p
a
o
r
m
o
r
r
a
p
a
n
c
o
s
e
c
e
n
n
v
v
o
o
x
c
y,
s
a
e
y
p
a
r
m
a
c
o
o
g
y
a
n
•
i
d
i
d
l
t
a
c
c
e
s
s
o
v
a
r
o
u
s
s
e
a
s
e
m
o
e
s
I
i
P
K
b
i
l
i
i
(
d
),
l
i
i
l
d
l
t
t
t
n
v
v
o
c
a
p
a
e
s
r
o
e
n
s
s
e
e
v
e
r
a
p
r
o
p
r
e
a
r
y
a
n
m
a
m
o
e
s
•

Platform for the developm ment of better targeted drugs

Complementary te echnologies

Integration of technology in value chain

® Ki Affi it®y

Scientifically and c commercially proven

High-end mass spectrome etry and world-class proteomics expertise

Cellular Target Pro compound's cellu ofiling - Revelation of a lar target spectrum

Overview Cellular Target P Profiling®

  • • Identification of on/off-target interactions in any cell type or tissue of or choice on a proteome-wide basis
  • • Determination of a compound's proteome-wide binding affinities
  • • Discrimination between high, medium and low affinity cellular targets
  • • Profiling against native, endogenously exp p ressed, post-translationally modified, full-length proteins
  • • Assessment of compound/target interactions in the presence of cellular co-factors and native complex partners

Overview KinAffinity®

  • • Identification of a kinase inhibitor's binding affinities to protein kinase targets expressed in any cell line or tissue
  • • Profiling g of kinase inhibitors against endogenously expressed full length proteins in the presence of cellular cofactors and native complex partners
  • • Revelation of interactions with protein kinases that are not detected by in vitro panel profiling
  • • Support of decision making in drug discovery to allow for risk assessment in kinase inhibitor selectivity analysis, optimization of lead compounds and selection of clinical candidates

Quantitative p p hos – monitor dynamic p ho roteomics c phosphorylation

Overview PhosphoScout®

  • • Allows global, unbiased annotation and quantif cells animal models and patient samples cells, and fication of regulated phosphorylation sites in living
  • • Currently more than 15,000 phosphorylation site samples es in living cells, animal models and patient
  • • Applications include mode of action analysis o discovery / diagnostics f targeted cancer drugs and biomarker

Current customerswith drug discover s are a good fit Technology ry alliances

Portfolio of discovery allia ances & Kinaxo's service partners

P
t
a
r
n
e
r
s		 F
o
c
s
a
r
e
a
u		 C
h
t
r
r
r
e
n
c
a
s
u
i
t
m
p
p
a
c		 U
i
d
f
p
s
e
o
r
E
t
o
e
c
v		 ´s
i
i
i
K
K
n
n
a
a
o
o
s
s
e
r
c
e
x
x
v
O
l
/
P
i
/
n
c
o
o
g
a
n
y
/
I
f
l
i
D
i
b
t
t
n
a
m
m
a
o
n
a
e
e
s		 + +
+
+		 t
p
a
r
n
e
r
s
:
i
D
b
t
a
e
e
s		 + +
+
+
C
S
N		 + +
i
P
a
n		 + +
+
U
d
i
l
d
n
s
c
o
s
e		 + +
+
A
i
n
a
e
m
a		 + +
+
C
S
N		 + +
V
i
a
r
o
s
u		 i
a
r
o
s
v
v
u		 i
a
r
o
s
v
u

Agenda

  • •Strategic Background
  • • Integration in Evotec's D Drug Discovery alliance business
  • • Financial implications & Outlook

Deal terms reflect components risk sharing idea and earn-out

Overview deal terms

•Number of shares: 115,6 mio • Only

  • •New Number of shares: 118,2 mio 1)
  • •Listing places: places:Frankfurt TecDAX,

OTCBB

•52 week high/low: € 3,47 / € 1.81

  • ec acquires 100% of all shares in Kinaxo
  • • Evotein sha15 mec pays at closing €3m in cash and approx. 2.6m ares, of which 650T shares are held in escrow for onths (reps and warranties)
  • • Evotecertabusinec pays up to €4 m to old shareholders in cash if ain events and revenue targets within joint ness plan are met
  • • Custoom representations and warranties
  • • Sharees are subject to lock-up provisions
  • technical closing conditions

Global reach for g lobal projects

Ca. 550 Evotec employees worldwide

Operations & sales representation

Strong strategic s ituation - impact for 2011ff

Key financials – Initial gui idance for 2011

in € m

Strategic imperativ ves for our business model

Next steps

Strrengthen core business

  • • EExpand quality leadership position in drug discovery
  • • I tnvest in highly innovative approaches to open new therapeutic routes in major markets (e.g. beta cell technology regenerative medicine oncology ) technology, medicine, oncology, …)

Up pgrade technology platform

Ilo( nvesti b t nes -in-cl thli t l t t lass technologies to accelerate "stoposs" or investment decisions in discovery (e.g. HTS, "in vivo models", …)

Evpro ven better and more drug discovery alliances & oduct development partnerships

  • • BhBuild even stronger portfolio of long-term high-quality partners quality
  • • Sp Selectively increase EVT risk component in selected partnerships

Building innovative drug discovery alliances

Your contact:

Dr Werner LanthalerChief Executive Officer

+49.(0).40.560 81-242 +49.(0).40.560 81-333 Fax [email protected]

More from Evotec SE

Director's Dealing 2026
May 22
Major Shareholding Notification 2026
May 21
Major Shareholding Notification 2026
May 19
Major Shareholding Notification 2026
May 18
Capital/Financing Update 2026
May 12
Regulatory Filings 2026
May 7
Interim / Quarterly Report 2026
May 6
Interim / Quarterly Report 2026
May 6
Director's Dealing 2026
May 5
Major Shareholding Notification 2026
May 5
View all filings →